Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

Income Statement

Follow revenue through to earnings.

Revenue

$35.58M

FY 2025 · Annual

+370.2% YoY

Operating Income

-$11.94M

FY 2025 · Annual

Net Income

-$17.89M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

VRCA Earnings Waterfall · TTM

NASDAQ:VRCA · Revenue to Net Income

Key Ratios

EPS$-1.56
Gross Margin85.8%
Net Margin-87.9%
P/E Ratio5.0
P/S Ratio8.9

Analysis

$37.2M of revenue converted into -$17.8M of net income for the selected period. Gross margin is 85.8% and net margin is -87.9%, showing how much revenue survives after costs and taxes. EPS is $-1.56, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipAug 18, 2026
4Statement of changes in beneficial ownershipAug 18, 2026

How much revenue does VRCA generate?

Verrica Pharmaceuticals Inc. (VRCA) reported $35.58M of revenue in fiscal 2025.

Is VRCA profitable?

Verrica Pharmaceuticals Inc. (VRCA) reported -$17.89M of net income, with a net margin of -50.3%.